These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
431 related articles for article (PubMed ID: 34515995)
1. Prognostic and predictive value of mismatch repair deficiency in gastric and gastroesophageal junction adenocarcinoma patients receiving neoadjuvant or adjuvant chemotherapy. Li Z; Wang Y; Ying X; Zhang L; Gao X; Jia Y; Zhang L; Wu A; Su X; Ji J J Surg Oncol; 2021 Dec; 124(8):1356-1364. PubMed ID: 34515995 [TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. André T; Tougeron D; Piessen G; de la Fouchardière C; Louvet C; Adenis A; Jary M; Tournigand C; Aparicio T; Desrame J; Lièvre A; Garcia-Larnicol ML; Pudlarz T; Cohen R; Memmi S; Vernerey D; Henriques J; Lefevre JH; Svrcek M J Clin Oncol; 2023 Jan; 41(2):255-265. PubMed ID: 35969830 [TBL] [Abstract][Full Text] [Related]
3. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022 [TBL] [Abstract][Full Text] [Related]
4. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials. Zaanan A; Shi Q; Taieb J; Alberts SR; Meyers JP; Smyrk TC; Julie C; Zawadi A; Tabernero J; Mini E; Goldberg RM; Folprecht G; Van Laethem JL; Le Malicot K; Sargent DJ; Laurent-Puig P; Sinicrope FA JAMA Oncol; 2018 Mar; 4(3):379-383. PubMed ID: 28983557 [TBL] [Abstract][Full Text] [Related]
5. Impact of mismatch repair deficiency on tumour regression grade after neoadjuvant chemotherapy in localized gastroesophageal adenocarcinoma. Heran M; Renaud F; Louvet C; Piessen G; Voron T; Lefèvre M; Dubreuil O; André T; Svrcek M; Cohen R Dig Liver Dis; 2023 Feb; 55(2):276-282. PubMed ID: 35780065 [TBL] [Abstract][Full Text] [Related]
6. Is Adjuvant Chemotherapy Necessary for Patients with Deficient Mismatch Repair Gastric Cancer?-Autophagy Inhibition Matches the Mismatched. Tsai CY; Lin TA; Huang SC; Hsu JT; Yeh CN; Chen TC; Chiu CT; Chen JS; Yeh TS Oncologist; 2020 Jul; 25(7):e1021-e1030. PubMed ID: 32058649 [TBL] [Abstract][Full Text] [Related]
7. Correlation between mismatch repair and survival of patients with gastric cancer after 5-FU-based adjuvant chemotherapy. Zhao F; Li E; Shen G; Dong Q; Ren D; Wang M; Zhao Y; Liu Z; Ma J; Xie Q; Liu Z; Li Z; Gao L; Zhao J J Gastroenterol; 2023 Jul; 58(7):622-632. PubMed ID: 37036516 [TBL] [Abstract][Full Text] [Related]
8. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy. Kim JE; Hong YS; Kim HJ; Kim KP; Lee JL; Park SJ; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Hoon KJ; Kim TW Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S630-7. PubMed ID: 26271397 [TBL] [Abstract][Full Text] [Related]
9. DNA mismatch repair deficiency but not ARID1A loss is associated with prognosis in small intestinal adenocarcinoma. González I; Goyal B; Xia MD; Pai RK; Ma C Hum Pathol; 2019 Mar; 85():18-26. PubMed ID: 30381262 [TBL] [Abstract][Full Text] [Related]
10. [Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment]. Cohen R; Pudlarz T; Garcia-Larnicol ML; Vernerey D; Dray X; Clavel L; Jary M; Piessen G; Zaanan A; Aparicio T; Louvet C; Tournigand C; Chibaudel B; Tougeron D; Guimbaud R; Benouna J; Adenis A; Sokol H; Borg C; Duval A; Svrcek M; André T Bull Cancer; 2020 Apr; 107(4):438-446. PubMed ID: 32057467 [TBL] [Abstract][Full Text] [Related]
11. Adjuvant Chemotherapy for Gastric Cancer Patients with Mismatch Repair Deficiency or Microsatellite Instability: Systematic Review and Meta-Analysis. Nie RC; Chen GM; Yuan SQ; Kim JW; Zhou J; Nie M; Feng CY; Chen YB; Chen S; Zhou ZW; Wang Y; Li YF Ann Surg Oncol; 2022 Apr; 29(4):2324-2331. PubMed ID: 34796431 [TBL] [Abstract][Full Text] [Related]
12. Two-Year Outcomes and Biomarker Analysis of Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma After Neoadjuvant Chemotherapy and Immunotherapy from the Phase II WuhanUHGI001 Trial. Sun X; Lyu J; Yang M; Lin Y; Wu K; Liu K; Li A; Shuai X; Cai K; Wang Z; Wang G; Zhang P; Yin Y; Tao K Ann Surg Oncol; 2024 Nov; 31(12):8157-8169. PubMed ID: 39154154 [TBL] [Abstract][Full Text] [Related]
13. Perioperative Chemotherapy Could Not Improve the Prognosis of Gastric Cancer Patients With Mismatch Repair Deficiency: A Multicenter, Real-World Study. Zhao L; Fu Y; Niu P; Zhang F; Jiao F; Zhou X; Wu Z; Wang W; Luan X; Han X; He M; Guan Q; Li Y; Zhao D; Gao J; Chen Y Oncologist; 2023 Oct; 28(10):e891-e901. PubMed ID: 37104872 [TBL] [Abstract][Full Text] [Related]
14. Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer. Korphaisarn K; Pongpaibul A; Limwongse C; Roothumnong E; Klaisuban W; Nimmannit A; Jinawath A; Akewanlop C World J Gastroenterol; 2015 Jan; 21(3):926-34. PubMed ID: 25624727 [TBL] [Abstract][Full Text] [Related]
15. Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial. Smyth EC; Fassan M; Cunningham D; Allum WH; Okines AF; Lampis A; Hahne JC; Rugge M; Peckitt C; Nankivell M; Langley R; Ghidini M; Braconi C; Wotherspoon A; Grabsch HI; Valeri N J Clin Oncol; 2016 Aug; 34(23):2721-7. PubMed ID: 27298411 [TBL] [Abstract][Full Text] [Related]
16. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors. Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271 [TBL] [Abstract][Full Text] [Related]
17. Mitochondrial DNA Copy Number as a Biomarker for Guiding Adjuvant Chemotherapy in Stages II and III Colorectal Cancer Patients with Mismatch Repair Deficiency: Seeking Benefits and Avoiding Harms. Chen M; Deng S; Cao Y; Wang J; Zou F; Gu J; Mao F; Xue Y; Jiang Z; Cheng D; Huang N; Huang L; Cai K Ann Surg Oncol; 2024 Sep; 31(9):6320-6330. PubMed ID: 38985229 [TBL] [Abstract][Full Text] [Related]
18. Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study. Nappo F; Fornaro L; Pompella L; Catanese S; Lavacchi D; Spallanzani A; Cappetta A; Puzzoni M; Murgioni S; Barsotti G; Tirino G; Pellino A; Vivaldi C; Strippoli A; Aprile G; Di Donato S; Mazza E; Prisciandaro M; Antonuzzo L; Zagonel V; Cascinu S; De Vita F; Lonardi S J Cancer Res Clin Oncol; 2023 Aug; 149(9):6601-6611. PubMed ID: 36795195 [TBL] [Abstract][Full Text] [Related]
19. Prognostic and predictive roles of DNA mismatch repair status in colon cancer patients treated with oxaliplatin-based chemotherapy: a retrospective study. Qin Q; Zhou AP; Yang L; Xu C; Sun YK; Zhang W; Wang JW; Zhong DS J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33316771 [TBL] [Abstract][Full Text] [Related]
20. Is pathologic tumor regression grade after neo-adjuvant chemotherapy a promising prognostic indicator for patients with locally advanced gastric cancer? A cohort study evaluating tumor regression response. Xu X; Zheng G; Zhang T; Zhao Y; Zheng Z Cancer Chemother Pharmacol; 2019 Sep; 84(3):635-646. PubMed ID: 31230156 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]